{"id":"hydroxychloroquine-combined-with-azithromycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Retinopathy (hydroxychloroquine)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxychloroquine is an antimalarial agent that accumulates in lysosomes and endosomes, inhibiting their acidification and interfering with viral entry and replication pathways. Azithromycin is a macrolide antibiotic with immunomodulatory properties that can reduce pro-inflammatory cytokine production. The combination was investigated for synergistic antiviral and anti-inflammatory effects, particularly in viral respiratory infections.","oneSentence":"Hydroxychloroquine inhibits endosomal acidification and toll-like receptor signaling while azithromycin provides macrolide antibiotic activity and immunomodulatory effects, together intended to reduce viral replication and inflammatory response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:12.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (investigational, Phase 3)"}]},"trialDetails":[{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":"Interstitial Lung Disease","enrollment":30},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04458948","phase":"PHASE2","title":"Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2020-03-24","conditions":"COVID-19","enrollment":28},{"nctId":"NCT04374903","phase":"NA","title":"Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients","status":"WITHDRAWN","sponsor":"King Hussein Cancer Center","startDate":"2022-04-01","conditions":"COVID-19 Patients","enrollment":""},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15},{"nctId":"NCT04345861","phase":"PHASE2, PHASE3","title":"Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2020-04-11","conditions":"Coronavirus Infection, Pneumonia, Viral","enrollment":7},{"nctId":"NCT05118984","phase":"PHASE4","title":"Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-02-16","conditions":"Meconium Stained, Azithromycin, Postpartum Endometritis","enrollment":324},{"nctId":"NCT05026801","phase":"PHASE3","title":"Azithromycin Plus Hydroxychloroquine for COVID-19 Infection","status":"WITHDRAWN","sponsor":"Iterum Therapeutics, International Limited","startDate":"2021-02-08","conditions":"Respiratory Tract Infection Viral","enrollment":""},{"nctId":"NCT04346693","phase":"PHASE3","title":"An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19","status":"COMPLETED","sponsor":"Burnasyan Federal Medical Biophysical Center","startDate":"2020-04-08","conditions":"Acute Respiratory Tract Infection, Acute Respiratory Insufficiency, Pneumonia","enrollment":320},{"nctId":"NCT04358081","phase":"PHASE3","title":"Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-05-01","conditions":"Covid-19","enrollment":20},{"nctId":"NCT04353180","phase":"PHASE3","title":"Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-08","conditions":"COVID19","enrollment":100000},{"nctId":"NCT04964583","phase":"PHASE2, PHASE3","title":"Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19","status":"UNKNOWN","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2021-01-20","conditions":"Covid19","enrollment":105},{"nctId":"NCT04933864","phase":"PHASE1","title":"COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-04-24","conditions":"SARS-CoV-2","enrollment":60},{"nctId":"NCT04459702","phase":"PHASE2","title":"A Study of Combination Therapies to Treat COVID-19 Infection","status":"WITHDRAWN","sponsor":"ProgenaBiome","startDate":"2020-07","conditions":"COVID, COVID-19, Corona Virus Infection","enrollment":""},{"nctId":"NCT04349592","phase":"NA","title":"Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-04-14","conditions":"Covid19","enrollment":456},{"nctId":"NCT04411433","phase":"PHASE3","title":"Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","status":"UNKNOWN","sponsor":"Ministry of Health, Turkey","startDate":"2020-05-08","conditions":"Sars-CoV2, COVID-19","enrollment":1008},{"nctId":"NCT04715295","phase":"PHASE4","title":"Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19","status":"UNKNOWN","sponsor":"Yaounde Central Hospital","startDate":"2020-10-05","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04370782","phase":"PHASE4","title":"Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting","status":"COMPLETED","sponsor":"St. Francis Hospital, New York","startDate":"2020-04-28","conditions":"COVID-19","enrollment":18},{"nctId":"NCT04361422","phase":"PHASE3","title":"Isotretinoin in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-12-01","conditions":"COVID-19","enrollment":300},{"nctId":"NCT04395768","phase":"PHASE2","title":"International ALLIANCE Study of Therapies to Prevent Progression of COVID-19","status":"UNKNOWN","sponsor":"National Institute of Integrative Medicine, Australia","startDate":"2020-09-09","conditions":"COVID19","enrollment":200},{"nctId":"NCT04347512","phase":"PHASE3","title":"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","status":"WITHDRAWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2020-06-02","conditions":"Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","enrollment":""},{"nctId":"NCT04341870","phase":"PHASE2, PHASE3","title":"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","status":"SUSPENDED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-11","conditions":"COVID19, SARS-CoV-2 Infection","enrollment":27},{"nctId":"NCT04355052","phase":"PHASE3","title":"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-04-11","conditions":"COVID - 19","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":116,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydroxychloroquine combined with Azithromycin","genericName":"Hydroxychloroquine combined with Azithromycin","companyName":"Ministry of Health, Turkey","companyId":"ministry-of-health-turkey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxychloroquine inhibits endosomal acidification and toll-like receptor signaling while azithromycin provides macrolide antibiotic activity and immunomodulatory effects, together intended to reduce viral replication and inflammatory response. Used for COVID-19 (investigational, Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}